Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonelokimab in Moderate to Severe Hidradenitis Suppurativa
NCT06411899Phase 3Completed
- Sponsor
- MoonLake Immunotherapeutics
- Start
- May 2024
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing sonelokimab with Placebo (2 arms). Primary endpoint: Hidradenitis Suppurativa Clinical Response 75 at 16 weeks. Started May 2024; status: completed.
02
Drugs
sonelokimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06411899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411899.